August 26 -- Zhejiang Conba Pharmaceutical (600572.SH) filed its net profit grew 66.49 percent year-on-year to 162 million yuan in the first half for EPS of 0.23 yuan, reports yicai.com. Affiliate Zhenjiang Jolly Pharmaceutical (300181) successfully listed in the first half. Conba’s holdings in Jolly were diluted to 19.5 percent from 26 percent. The company recorded investment return of 67.86 million yuan from Jolly.

Revenue from plant-based medicines and chemical pharmaceuticals grew 8.05 percent and 15.97 percent year-on-year to 413 million yuan and 212 million yuan in the first half, respectively.

On August 24, parent company Conba Group and effective controller Hu Jiqiang jointly announced that they will inject Zhejiang Conba Chinese Medicine and Zhejiang Inofa Pharmaceutical into Conba. The net margins of Conba Chinese Medicine and Inofa were 7.89 percent and 7.44 percent in the first seven months.